Consensus Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/06/2026 BST			5-day change	1st Jan Change
18.67 ^USD	+1.97%		+3.04%	+19.07%

05-07	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT

Evolution of the Average Target: Monte Rosa Therapeutics, Inc.

Evolution of the Target Price: Monte Rosa Therapeutics, Inc.

Changes in Analyst Recommendations: Monte Rosa Therapeutics, Inc.

a666f0e8b9.Sbd_sBI8-HDxb5WTOcXwNZCYaaO8jeuQ-Q0dWBkAbyI.I-gN_2JjyQGaKtneeKiKU9KoNvnu56agjWNbIHJHC2E-7yzvfFmiPYY5oQ~308914a47fc4d081fa542b3cdafbc3eb

Analysts' recommendations: Monte Rosa Therapeutics, Inc.

12-16	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating	MT
12-16	Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13	MT
15/09/25	Wedbush Raises Price Target on Monte Rosa Therapeutics to $19 From $17, Maintains Outperform Rating	MT
21/03/25	Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $17 From $15, Maintains Outperform Rating	MT
19/12/24	Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14	MT
28/10/24	Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating	MT
29/04/24	UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating	MT
15/02/24	Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target	MT
17/03/23	Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating	MT
03/01/23	Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18	MT
13/10/22	UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target	MT
15/08/22	Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target	MT
12/05/22	Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating	MT
28/04/22	Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target	MT
30/03/22	Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating	MT
10/02/22	Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target	MT
03/01/22	Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating	MT
17/11/21	Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target	MT
14/10/21	MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating	MT
19/07/21	MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target	MT
19/07/21	MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MONTE ROSA THERAPEUTICS, INC.					+73.18%
	LONZA GROUP AG					+32.6%
	REVOLUTION MEDICINES, INC.					+12.95%
	BEONE MEDICINES AG					+51.71%
	IQVIA HOLDINGS INC.					+34.36%
	CELLTRION, INC.					+50.76%
	ASCENDIS PHARMA A/S					+29.96%
	MEDPACE HOLDINGS, INC.					-2.67%
	EUROFINS SCIENTIFIC SE					+11.89%
	IONIS PHARMACEUTICALS, INC.					+38.24%
	Average					+33.30%
	Weighted average by Cap.					+31.42%